Stereotaxis, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Stereotaxis designs and markets robotic magnetic navigation systems, instruments, disposable devices, and information systems for interventional laboratories, with a primary focus on cardiac electrophysiology and potential expansion into coronary, neurovascular, and peripheral procedures. The filing covers the three months ended March 31, 2024, and was filed May 15, 2024.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $6.9 million | $6.5 million | +5% |
| Systems revenue | $2.6 million | $1.8 million | +43% |
| Disposables, service and accessories | $4.3 million | $4.7 million | -10% |
| Gross profit | $4.0 million | $3.9 million | +2% |
| Gross margin | 58% | 59% | -1 percentage point |
| Operating loss | $4.7 million | $5.6 million | Loss narrowed by $0.9 million |
| Net loss | $4.5 million | $5.3 million | Loss narrowed by $0.8 million |
| Net loss attributable to common stockholders | $4.8 million | $5.7 million | Loss narrowed by $0.8 million |
| Basic and diluted loss per share | $0.06 | $0.07 | Improved |
| Cash used in operating activities | $2.3 million | $2.8 million | Improved by $0.5 million |
Systems revenue represented 38% of revenue versus 28% in the prior-year period. Disposables represented 21% versus 24%, while other recurring revenue represented 41% versus 48%. Operating expenses were $8.7 million, down from $9.5 million, including research and development expense of $2.2 million, sales and marketing expense of $3.0 million, and general and administrative expense of $3.5 million.
Cash, Liquidity, Debt and Capital Resources
- Cash and cash equivalents were $17.6 million at March 31, 2024, compared with $19.8 million at December 31, 2023.
- Total cash, cash equivalents, and restricted cash were $18.2 million at March 31, 2024, compared with $20.6 million at year-end 2023.
- Working capital was $18.4 million, down from $20.0 million at December 31, 2023.
- The Company reported no debt. Operating lease liabilities totaled $5.4 million, with future minimum operating lease payments of $7.5 million before $2.1 million of interest.
- Cash used in operating activities was $2.3 million. Investing cash flow was zero, and financing activities provided less than $0.1 million.
- Stock-based compensation was $2.6 million in the quarter, including $1.8 million related to the CEO Performance Award.
Material Changes Versus the Prior Comparable Period
- Revenue increased 5%, primarily due to higher system sales volume and product mix.
- Disposables, service, and accessories revenue declined approximately 10%, driven by lower time-and-material service revenue and lower disposable sales related to Biosense Webster catheter shortages.
- Gross margin declined modestly to 58% from 59%. Systems gross profit improved to approximately $0.7 million from $0.1 million, while gross margin on disposables, service, and accessories declined to 76% from 79%.
- Research and development expense decreased 18%, primarily from project timing and lower headcount-related costs, partly offset by higher clinical trial costs.
- Cash used in operations improved by approximately $0.5 million, but the Company remained cash-flow negative.
- Series A convertible preferred stock outstanding declined by 450 shares, which converted into 998,668 common shares. The preferred stock remains entitled to a 6% cumulative dividend and may be converted into approximately 48.9 million common shares based on the filing’s disclosed amount.
- Common shares outstanding increased to 82.1 million at March 31, 2024, from 80.9 million at December 31, 2023.
Outlook, Commentary, Risks and Unusual Items
The filing does not provide quantitative revenue, earnings, cash-flow, or margin guidance. Management states that quarterly results are not necessarily indicative of full-year results.
- On May 11, 2024, after quarter-end, Stereotaxis agreed to acquire Access Point Technologies, Inc., a developer of electrophysiology catheters, for $3.0 million of Stereotaxis common stock at closing plus additional shares contingent on regulatory and commercial milestones over five years. Closing is expected by the end of the third quarter of 2024, subject to customary conditions.
- Management identifies continuing risks from supply-chain disruptions, component shortages, inflation, logistics delays, and increased manufacturing costs.
- Hospital staffing and cost pressures may delay or cancel capital projects, extend sales and installation cycles, and reduce procedure volumes and disposable demand.
- Capital-market disruptions could limit the Company’s ability to raise additional capital on acceptable terms if needed. The filing does not state that additional financing is currently committed.
- Regulatory approvals for the MAGiC catheter and market expansion remain uncertain and may require additional data or face denial.
- Strategic relationships supporting compatible imaging, mapping, catheter, and other systems are important to commercialization and may not continue on acceptable terms.
- A vendor filed UCC financing statements on approximately $0.6 million of underlying inventory in February 2024. The Company believes the filings are without merit and intends to contest them.
- The Company has approximately $11.9 million of remaining performance obligations on system contracts as of March 31, 2024, generally expected to be recognized within two years, although some obligations may extend longer.
- Management concluded that disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Whether system sales growth can continue and offset weakness in disposable, service, and accessory revenue.
- The effect and duration of Biosense Webster catheter shortages on procedure volumes and recurring revenue.
- Cash-burn trends, available liquidity, and whether future operating losses will require additional financing.
- Terms, dilution, milestone conditions, and closing status of the proposed Access Point Technologies acquisition.
- The potential dilution from the Series A preferred stock, options, restricted stock units, and other equity awards.
- Progress and timing of regulatory approvals for the MAGiC catheter and other international market registrations.
- Resolution and potential financial impact of the vendor’s approximately $0.6 million UCC filings.
- Exposure to supply-chain, hospital-capital-spending, regulatory, and strategic-partner risks described in the filing.